Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic Kidney Disease-Associated Anemia Condition: Patient not on dialysis |
Dose: Intravenous/Subcutaneous Injection – 50-100 units/kg Frequency: 3 times weekly Note: Initial dose. Initiate only when (1) hemoglobin level less than 10 g/dL, (2) rate of hemoglobin decline indicates likely necessity of red blood cell transfusion, and (3) reducing risk of alloimmunization or other risks related to red blood cell transfusion is goal; if hemoglobin level greater than 10 g/dL, reduce or interrupt dose and use lowest dose sufficient to reduce need for red blood cell transfusion. |
|
Indication: Chronic Kidney Disease-Associated Anemia Condition: Patient on dialysis |
Dose: Intravenous Injection – 50-100 units/kg Frequency: 3 times weekly Note: Initial dose. Initiate when hemoglobin level less than 10 g/dL; if hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt dose. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic Kidney Disease-Associated Anemia Age: less than 1 month |
Dose: Safety and efficacy not established Note: Safety and efficacy not established |
|
Indication: Chronic Kidney Disease-Associated Anemia Age: greater than 1 month |
Dose: Intravenous or Subcutaneous Injection – 50 units/kg Frequency: three times weekly Note: initially; if patient on dialysis, intravenous route recommended; Initiate when hemoglobin level less than 10 g/dL; if hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt dose |
Administration
- For subcutaneous or IV use
- Give as directed
Side Effect
- Pyrexia (10-42%)
- Nausea (11-35%)
- Hypertension (14-27%)
- Cough (4-26%)
- Vomiting (12-28%)
- Pruritus (12-21%)
- Rash (2-19%)
- Headache (5-18%)
- Arthralgias (10-16%)
- Arthralgia (10%)
- Myalgia (10%)
- Stomatitis (10%)
- Diarrhea (9%)
- Dizziness (9%)
- Edema (9%)
- Fatigue (9%)
- Weight decrease (9%)
- Medical device malfunction (artificial kidney clotting during dialysis) (8%)
- Vascular occlusion (vascular access thrombosis) (8%)
- Vomiting (8%)
- Asthenia (7%)
- Chest pain (7%)
- Injection-site irritation (7%)
- Muscle spasm (7%)
- Upper respiratory tract infection (URTI) (URTI) (7%)
- Urticaria (3%)
- Seizures (2.5%)
- Pulmonary embolism (1%)
- Respiratory tract congestion (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Cyclosporine, hematinic agents, drugs that decrease erythropoiesis
|
Interactions noted, but effects not specified
|
|
Hematinic agents
|
Potentiated by
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypersensitivity to Albumin
|
Risk of severe allergic reaction
|
|
Uncontrolled Hypertension
|
Risk of blood pressure crisis
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 2ºC to 8ºC. Do not freeze or shake. This temperature range should be closely maintained until administration to the patient. Store in original package in order to protect from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.